BERG named visionary in first-ever Frost Radar AI in Drug Discovery report
.jpg)
The biotech pioneer is one of the first companies to develop corporate partnerships in this application of artificial intelligence (AI) for drug discovery.
BERG, a clinical-stage biotech company that uses AI to research diseases and develop innovative treatments, has been awarded a spot in Frost & Sullivan's first-ever Frost Radar AI in Drug Discovery report in the pharmaceutical industry.
Frost & Sullivan's decision to recognize BERG as a biotech pioneer is based on its strong innovation trajectory, sustained growth over the last decade and being one of the first companies to develop corporate partnerships in this application.
BERG's capabilities also uniquely position the company to apply AI technologies to patient data to better understand the biological drivers of disease.
Amol Jadhav, Industry Analyst, Transformational Health, said: "Their inventive research efforts, understanding of diagnostics and drug development combined with the AI-powered approach have put them at the forefront of precision medicine."
Frost & Sullivan identified BERG as a Visionary in AI drug discovery for a number of reasons:
Dr Niven R. Narain, BERG's President and Chief Executive Officer said they will continue to work with partners to identify "what's next" across multiple sectors including oncology, neurology and rare diseases.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.